Overview

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study will determine whether the negative effects of combined oral contraceptive (COC) therapy on the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis and bone turnover are dependent on the route of administration such that an attenuation of these effects is observed when a comparable dose of non-oral transdermal contraceptive (TDC) and contraceptive vaginal ring therapy (CVR) are also tested.
Phase:
Phase 4
Details
Lead Sponsor:
Penn State University
Collaborators:
Massachusetts General Hospital
Purdue University
Treatments:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Ethinyl Estradiol
NuvaRing